AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer
Jung‐Yun Lee(Yonsei University), Lingying Wu(Chang Gung University), Sathana Boonyapipat(Songklanagarind Hospital), Chih‐Long Chang(Mackay Memorial Hospital), Guangwen Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), Ivan Sinielnikov, Li Wang(Zhengzhou University), Yong‐Man Kim(Asan Medical Center), Hee Seung Kim(Seoul National University), W. Wang(Shanxi Medical University), Yujuan Gao(China Pharmaceutical University), Т. Андабеков(National Research Center for Hematology Russian Academy of Medical Sciences), Xiang Zhang(Fudan University), Hu Liu(Anhui Provincial Hospital), Kai Wang(Harvard University), Tao Wang(Tongji Hospital), Jeong‐Won Lee(Korea University), Danbo Wang(Qinghai University), Xiyan Mu(BeiGene (China)), Desheng Yao(Guangxi Medical University)
Cited by 7
Related Papers
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|214